This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

About

Burden of Disease

Burden of Disease

Description of the DiseaseGlobal EpidemiologyIndian EpidemiologyPneumococcal Disease and InfluenzaChallenges

Risk Factors
 

Risk Factors

Secondary Infections
​​​​​​​

Secondary Infections

Mechanism of Action
​​​​​​​

Mechanism of Action

Prevention of Pneumococcal Disease
 

Polysaccharide VaccineConjugate VaccineDifference

Need for Pneumococcal Vaccination

In ElderlyIn India

Cost-effectiveness of PCV13
 

NeedIndian StudiesGlobal Studies

Legacy of Prevenar
 

ManufacturingCRM197Activation and ConjugationPneumococcal Disease and InfluenzaDistributionVideos

Safety
 

Safety

Conclusion
 

Conclusion
Dosing

Dosing
 

Adults ≥18 Years of AgeAdults ≥50 Years of AgeCOVID VaccinationFlu Vaccination
Efficacy

Prevenar 13® Clinical Experience
 

IntroductionClinical Trials

Efficacy of Prevenar 13®
 

IntroductionStudyObjectiveMethodologyCriteriaResultsConclusion

Effectiveness of Prevenar 13® 
 

IntroductionObjectiveMethodologyAnalysisResultsLimitationsLearningsConclusion

Indian Clinical Trials
 

IntroductionStudy DesignResultsLimitationsConclusion
Recommendations for Use

Recommendations for Use
 

ACIP 2019NCCN 2020RSSDI 2020IMA GuidelinesIAOH Guidelines for Working AdultsClinical Practice Guidelines 2019 (ICS/NCCP)The Geriatric Society of India, 2015Indian Society of Nephrology
FAQs

PCV13 in Pulmonology
 

RoleComplicationsClinical DataRecommendations

PCV13 in Nephrology
 

RoleClinical DataRecommendations

PCV13 in Oncology
 

RoleClinical DataRecommendations

PCV13 in Rheumatology
 

RoleComplicationsDataRecommendationsConsensus

PCV13 in Diabetes
 

RoleComplicationsDataRecommendations

PCV13 in HIV Infection
 

RoleBurdenPulmonary InfectionDataEfficacyRecommendations

PCV13 in Cardiology
 

RoleBurdenComplicationsDataRecommendations
Resources

Resources

Summary of Prescribing InformationDownloadable ResourcesEvents and WebinarsLatest Articles

Recommendations

What Are the National and Global Recommendations for the Use of Pneumococcal Vaccines in Chronic Lung Disease?

   

Pneumococcal vaccination is recommended for use in patients with chronic lung diseases, including COPD,by various global bodies and respiratory societies, like GOLD (2020), Swiss Respiratory Society (2013), British Columbia Medical Association (2011), CDC’s ACIP (2019), the Portuguese Respiratory Society (2014), the Spanish Society of Pneumology and Thoracic Surgery, the Philippine Society for Microbiology and Infectious Diseases and Royal College of Physicians of Thailand.1-8

   

CDC’s ACIP (2019) recommends the use of PCV13 in persons aged ≥65 years with chronic lung diseases based on shared clinical decision-making. One dose of PPSV23 is recommended for persons aged <65 years with chronic lung disease. For persons aged ≥65 years, 1 dose of PPSV23 is recommended; if PCV13 has been administered, then PPSV23 should be given ≥1 year after PCV13 and ≥5 years after any PPSV23 at age <65 years. The Portuguese Respiratory Society (2014) recommended the sequential administration of PCV13 and PPSV23 in adults aged ≥50 years with chronic respiratory diseases, including chronic asthma under inhaled corticosteroid. The Spanish Society of Pneumology and Thoracic Surgery (2013) in a joint consensus document recommended the use of PCV13 in chronic respiratory diseases (including COPD, asthma and interstitial lung disease). The Philippine Society for Microbiology and Infectious Diseases and Royal College of Physicians of Thailand also recommended the use of PCV13 in patients with chronic lung diseases.7,8

   

The API (2014) recommended the use of pneumococcal vaccines in adults aged ≥50 years with predisposing conditions, including chronic lung disease. Other national guidelines that recommend the use of pneumococcal vaccines in chronic lung diseases include those from the IAOH (2020), IMA, etc. The IAOH, API and IMA recommend the use of PCV13 and PPSV23 in high-risk adults aged between 50 and 64 years. The high-risk group of adults includes patients with COPD. In these cases, PCV13 should be administered first followed by PPSV23 after 8 weeks. Thereafter, PPSV23 can be repeated after 5 years.9-11

   

   

ACIP, Advisory Committee on Immunization practices; API, Association of Physicians of India; CDC, Centers for Disease Control and Prevention; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IMA, Indian Medical Association; IAOH, Indian Association of Occupational Health; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal plain polysaccharide vaccine.

   

References:

Global strategy for the diagnosis, management and prevention of COPD. 2020 report. Global Initiative for Chronic Obstructive Lung Disease. Accessed May 17, 2022. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdfRussi EW, Karrer W, Brutsche M, et al. Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory Society. Respiration. 2013;85:160-174.Chronic obstructive pulmonary disease (COPD): diagnosis and management. British Columbia Medical Association. Accessed May 17, 2022. https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/bc-guidelines/copd_full_guideline.pdfMatanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-1075.Froes F, Diniz A, Cordeiro CR, Serrado M, de Almeida AR; Portuguese Respiratory Society. Consensus document for the prevention of respiratory infections in adults. Rev Port Pneumol. 2014;20(2):111-114.
Picazo JJ, González-Romo F, Rojas AG, et al. Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions. Rev Esp Quimioter. 2013;26(3):232-252.Recommendations. Philippine Society for Microbiology and Infectious Diseases. Accessed May 17, 2022. https://www.psmid.org/wp-content/uploads/2020/03/CPG-ADULT-IMMUNIZATION-2018.pdfRecommendations. Royal College of Physicians of Thailand. Accessed May 17, 2022.http://www.rcpt.org/index.php/news/2012-09-24-09-26-20/111.html
Dhar R. Review of guidelines for the use of vaccines to prevent community-acquired pneumonia in Indian adults. JAPI. 2016;64:45-51. Accessed May 17, 2022. https://www.japi.org/u2b4d4c4/review-of-guidelines-for-the-use-of-vaccines-to-prevent-community-acquired-pneumonia-in-indian-adultsKoul PA, Swaminathan S, Rajgopal T, et al. Adult immunization in occupational settings: a consensus on Indian experts. Indian J Occup Environ Med. 2020;24:3-15.Tandon RN, Ravindra W, Monga VK. Life Course Immunization Guidebook. A Quick Reference Guide. Indian Medical Association; 2018. Accessed May 17, 2022.
http://www.ima- india.org/ima/pdfdata/IMA_LifeCourse_Immunization_Guide_2018_DEC21.pdf

   

Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

   

PP-PRV-IND-0268 July 2022


PCV13 in Pulmonology

Dosing

Help protect your adult patients against pneumococcal pneumonia with single-dose administration

Learn more


Efficacy

Efficacy proven by the CAPiTA study

Learn more


Recommendations for Use

The ACIP recommends routine use of PCV13 among adults

Learn more

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-PRV-IND-0268

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 14 July 2022
Yes No
You are now leaving PfizerPro website

​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
​PP-UNP-IND-0012 14 July 2022